Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The structural and functional alterations of high density lipoproteins (HDL) levels in type 2
diabetes (T2D) patients linked to hypertriglyceridemia, hyperglycemia, insulin resistance,
inflammation and oxidation, play a major role in the increased macrovascular risk in these
patients. An impaired function of the adipose tissue (AT) in T2D contributes to low HDL
concentrations.
Objectives: 1) Quantitative and qualitative characterisation of HDL subclasses by
ultracentrifugation, proteomic and metabolomic techniques. 2) To study the relationship
between the HDL subclasses, preβ1 HDL and remnant HDL, and clinical determinants of
arteriosclerosis. 3) Functional in vitro studies of the HDL subclasses determined in
Objective 1. 4) To study the role of AT determining the low HDL levels. 5) To study the
impact of HDL increasing drugs on HDL qualitative changes.
Phase:
Phase 4
Details
Lead Sponsor:
Institut Investigacio Sanitaria Pere Virgili
Collaborator:
Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders